RECK and neoplasm: Finally, when the CRISPR-Cas13a system was delivered by the CHAIN in vivo, it knocked down the targeted oncogene miR-21, restored PDCD4 and RECK, crippled downstream MMP-2, and eventually suppressed tumor growth.